- Home
- INCY vs RRX Comparison
INCY vs RRX Comparison
Compare INCY & RRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INCY | RRX |
|---|---|---|
| Founded | 1991 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.1B |
| IPO Year | 1994 | 1994 |
Fundamental Metrics
Financial Performance| Metric | INCY | RRX |
|---|---|---|
| Price | $118.87 | $210.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 10 |
| Target Price | $103.52 | ★ $210.70 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.69% |
| EPS Growth | ★ 4173.33 | 42.86 |
| EPS | ★ 1.47 | 0.96 |
| Revenue | ★ $3,394,635,000.00 | $3,257,100,000.00 |
| Revenue This Year | $10.44 | $4.20 |
| Revenue Next Year | $10.99 | $12.13 |
| P/E Ratio | ★ $80.05 | $221.60 |
| Revenue Growth | ★ 13.67 | 5.21 |
| 52 Week Low | $71.00 | $127.96 |
| 52 Week High | $119.60 | $247.80 |
Technical Indicators
Market Signals| Indicator | INCY | RRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 45.00 |
| Support Level | $98.50 | $198.57 |
| Resistance Level | $119.29 | $220.40 |
| Average True Range (ATR) | 3.18 | 8.64 |
| MACD | -0.34 | -0.48 |
| Stochastic Oscillator | 84.14 | 37.57 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.